The use of biologic therapies for off-label conditions in daily clinical practice is increasing, yet few studies have detailed the safety of these agents with regards to infection in patients with systemic autoimmune disease. New research offers a glimpse at the infection rates in these vulnerable patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Díaz-Lagares, C. et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res. Ther. 13, R112 (2011).
Furst, D. E. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann. Rheum. Dis. 70 (Suppl. 1), i2–i36 (2011).
Carmona, L. et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology 50, 85–92 (2011).
Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).
Dixon, W. G. et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 56, 2896–2904 (2007).
Curtis, J. R. et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann. Rheum. Dis. 70, 1401–1406 (2011).
Ippolito, A & Petri, M. An update on mortality in systemic lupus eruthematous patients. Clin. Exp. Rheum. 26, S72–S79 (2008).
Terrier, B. et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62, 2458–2466 (2010).
Terrier, B. et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res. (Hoboken) 62, 1787–1795 (2010).
Stone, J. H. et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 54, 1608–1618 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K. L. Winthrop has acted as a consultant for Abbott, Amgen, Genentech and Lilly, and has received grant/research support and acted as a consultant for Pfizer. J. S. Smolen has acted as a consultant and received grant/research support from Bristol–Myers Squibb, Centour, MSD, Pfizer, Roche, UCB.
Rights and permissions
About this article
Cite this article
Winthrop, K., Smolen, J. Off-label biologics use and infection risk—the great unknown. Nat Rev Rheumatol 7, 685–686 (2011). https://doi.org/10.1038/nrrheum.2011.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.154
This article is cited by
-
Off-label use of the expensive orphan drug eculizumab in France 2009–2013 and the impact of literature: focus on the transplantation field
European Journal of Clinical Pharmacology (2016)
